Canadian pharma wins licence dispute as another continues
A Canadian pharmaceuticals company has defeated an ICC claim brought against it by an Irish counterpart over the marketing of a drug used to treat a chronic intestinal condition, as a separate US$365 million claim it faces from an Italian company continues.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.